Tumor antigen-associated autoantibodies (TAAbs) are generated by the immune system in response to tumor-associated antigens (TAAs). The underlying mechanisms of their production remain incompletely understood, yet may encompass factors such as aberrant protein expression, deficiencies in immune tolerance, the tumor inflammatory microenvironment, exosomes, and immunogenic cell death. TAAbs exert a dual effect in tumor initiation and progression, both facilitating and impeding the development of malignant tumors. They represent promising biomarkers for early tumor diagnosis, prognosis assessment, and evaluation of treatment efficacy or outcomes, thereby emerging as a current research focal point. This review initially clarifies the multidimensional mechanisms and dual functions of TAAbs in tumorigenesis and tumor progression, and subsequently explores their application prospects in tumor diagnosis, treatment, and prognosis. Finally, through a summary and analysis of the current research landscape, three crucial and feasible future research directions are put forward. It should be underscored that TAAb detection is a promising adjunctive instrument for tumor diagnosis and treatment; however, it still confronts substantial challenges in clinical application and necessitates further in-depth exploration.

Chemoimmunotherapy has evolved as a standard treatment for advanced non-small cell lung cancer (aNSCLC). However, inevitable drug resistance has limited its efficacy, highlighting the urgent need for biomarkers of chemoimmunotherapy. A three-phase strategy to discover, verify, and validate longitudinal predictive autoantibodies (AAbs) for aNSCLC before and after chemoimmunotherapy was employed. A total of 528 plasma samples from 267 aNSCLC patients before and after anti-PD1 immunotherapy were collected, plus 30 independent formalin-fixed paraffin-embedded samples. Candidate AAbs were firstly selected using a HuProt high-density microarray containing 21,000 proteins in the discovery phase, followed by validation using an aNSCLC-focused microarray. Longitudinal predictive AAbs were chosen for ELISA based on responders versus non-responders comparison and progression-free survival (PFS) survival analysis. Prognostic markers were also validated using immunohistochemistry and publicly available immunotherapy datasets. We identified and validated a panel of two AAbs (MAX and DHX29) as pre-treatment biomarkers and another panel of two AAbs (MAX and TAPBP) as on-treatment predictive markers in aNSCLC patients undergoing chemoimmunotherapy. All three AAbs exhibited a positive correlation with early responses and PFS (p < 0.05). The kinetics of MAX AAb showed an increasing trend in responders (p < 0.05) and a tendency to initially increase and then decrease in non-responders (p < 0.05). Importantly, MAX protein and mRNA levels effectively discriminated PFS (p < 0.05) in aNSCLC patients treated with immunotherapy. Our results present a longitudinal analysis of changes in prognostic AAbs in aNSCLC patients undergoing chemoimmunotherapy.

Abstract Background Research on the antinuclear antibodies (ANA) profile across different pathological subtypes of lymphoma was limited. Our study aimed to assess ANA profile and investigate its potential prognostic value in lymphoma. Method We collected plasma samples from 139 lymphoma patients and analyzed the expression of plasma ANA, SSA, and SSB using the enzyme-linked immunosorbent assay (ELISA). Additionally, we focused on B-cell non-Hodgldn’s lymphoma (B-NHL) for survival analysis. Results Influencing factors for ANA profile levels included age (ANA: P = 0.0035, SSA: P = 0.0553, SSB: P = 0.0025), gender (SSA: P = 0.0436), serum IgG (ANA, P = 0.0385; SSA, P = 0.0175; SSB, P = 0.0291), and erythrocyte sedimentation rate (ESR) (SSA: P = 0.0380). In subtype comparisons, ANA and SSB levels were significantly lower in low-grade B-NHL compared to Hodgkin lymphoma (HL) (low-grade B-NHL vs. NHL: ANA, P = 0.0107; SSB, P = 0.0126). Aggressive NHL exhibited a higher ANA profile compared to indolent NHL (aggressive NHL vs. indolent NHL: ANA, P = 0.0262; SSA, P = 0.0136; SSB, P = 0.0280). Kaplan–Meier analyses identified SSA and SSB as potential prognostic biomarkers in patients with B-NHL undergoing chemotherapy. Conclusion Our study evaluated ANA profile in various subtypes of lymphoma and demonstrated the prognostic value of autoantibodies in predicting clinical outcomes. The results highlight the potential of incorporating ANA profile into the prognostic assessment of lymphoma.

COVID-19 inactivated vaccine-induced humoral responses in patients with lung cancer (LCs) to SARS-CoV-2 wild-type (WT) strain and variants BA.4/5 after the primary 2-dose and booster vaccination remained unknown. We conducted a cross-sectional study in 260 LCs, 140 healthy controls (HC) and additional 40 LCs with serial samples by detecting total antibodies, IgG anti-RBD and neutralizing antibodies (NAb) toward WT and BA.4/5. SARS-CoV-2-specific antibody responses were augmented by the booster dose of inactivated vaccines in LCs, whereas they were lower than that in HCs. Enhanced humoral responses waned over time after triple injection, notably in NAb against WT and BA.4/5. The NAb against BA.4/5 was much lower than WT. Age ≥ 65 was risk factor for immunization of NAb to WT. Undergoing treatment resulted in a lower antibody response than those without and radiotherapy was a also risk factor for seroconversion of NAb to WT. Lower lymphocyte counts contributed to a lower titer of IgG anti-RBD and NAb against BA.4/5 in LCs than HCs. Specifically, total B cells, CD4+T cells and CD8+T counts were correlated with the humoral response. These results should be taken into consideration for the elderly patients under treatment.

PURPOSE:Early diagnosis is crucial for optimal prognosis of gastric cancer (GC). Hereby, we aimed to identify novel serum autoantibody-based biomarkers for precancerous lesion (PL) and early GC. METHODS:We performed serological proteome analysis (SERPA) combined with nanoliter-liquid chromatography combined with quadrupole time of flight tandem mass spectrometry (Nano-LC-Q-TOF-MS/MS) to screen for GC-associated autoantibodies. The identified autoantibodies were analyzed for potential detection value for PL and GC by enzyme-linked immunosorbent assay (ELISA). Receiver operating characteristic (ROC) curves analysis was conducted to evaluate the accuracy of the biomarkers. RESULTS:We identified seven candidates, such as mRNA export factor (RAE1), Nucleophosmin 1 (NPM1), phosphoglycerate kinase 1 (PGK1), and ADP-ribosylation factor 4 (ARF4). Antibodies against all seven proteins were present at higher levels in sera from 242 patients (51 PL, 78 early GC, 113 advanced GC) compared with sera from 122 healthy individuals. RAE1-specific autoantibody discriminated best between patients at different GC stages, with area under the curve (AUC) values of 0.710, 0.745, and 0.804 for PL, early GC, and advanced GC, respectively. Two predictive models composed of gender, RAE1, PGK1, NPM1, and ARF4 autoantibodies (Model 2 for PL) and of age, gender, RAE1, PGK1, and NPM1 autoantibodies (Model 3 for early GC) had improved diagnostic efficiencies, with AUCs of 0.803 and 0.857, sensitivities of 66.7% and 75.6%, and specificities of 78.7% and 87.7%, respectively. CONCLUSION:The identified serum tumor-associated autoantibodies (TAAbs) may have good potential for early detection of GC and PL.

BACKGROUND:Research on immunogenicity after 3rd SARS-CoV-2 vaccine in elder hepatocellular carcinoma (HCC) was limited. This study aimed to investigate the efficacy and influencing factors of inactivated SARS-CoV-2 vaccine in elder HCC. RESEARCH DESIGN AND METHODS:We assessed total antibodies, anti-RBD IgG, and neutralizing antibodies (NAb) toward SARS-CoV-2 wild type (WT) as well as BA.4/5 in 304 uninfected HCC, 147 matched healthy control (HC), and 53 SARS-CoV-2 infected HCC, all aged over 60 years. The levels of antibodies were compared in the period 7-90, 91-180, and >180 days after 2nd or 3rd vaccination, respectively. RESULTS:HCC had lower seropositivity than HC after 2nd dose (total antibodies, 64% vs. 92%, P < 0.0001; anti-RBD IgG, 50% vs. 77%, P < 0.0001). But 3rd dose can efficaciously close the gap (total antibodies, 96% vs. 100%, P = 0.1212; anti-RBD IgG: 87% vs. 87%, P > 0.9999). Booster effect of 3rd dose can persist >180 days in HCC (2nd vs. 3rd: total antibodies, 0.60 vs. 3.20, P < 0.0001; anti-RBD IgG, 13.86 vs. 68.85, P < 0.0001; WT NAb, 11.70 vs. 22.47, P < 0.0001). Vaccinated HCC had more evident humoral responses than unvaccinated ones after infection (total antibodies: 3.85 vs. 3.20, P < 0.0001; anti-RBD IgG: 910.92 vs. 68.85, P < 0.0001; WT NAb: 96.09 vs. 22.47, P < 0.0001; BA.4/5 NAb: 86.53 vs. 5.59, P < 0.0001). CONCLUSIONS:Our findings highlight the booster effect and protective role of 3rd dose. Our results could provide a theoretical foundation for informing decisions regarding SARS-CoV-2 vaccination in elder HCC.

外周血细胞形态学是保证血常规分析结果准确性的重要手段,也是血液病筛查、辅助诊断的经典方法,一直是检验医学科住院医师规范化培训(简称住培)及考核的重点和难点.中国医学科学院北京协和医学院肿瘤医院(简称我院)检验医学科专业基地以《住院医师规范化培训内容与标准(2022年版)——检验医学科培训细则》 及《北京地区住院医师规范化培训标准——医学检验科培训细则》 为指导,在培训中应用多元化的教学方法,实施递进式的教学流程并结合多种考核形式,逐步建立起将翻转课堂、案例教学、实操演练与临床实战相结合的外周血细胞形态学教学模式.在北京市住培一阶段结业技能考核中,我院检验医学科住院医师通过率为100％,为培养具有岗位胜任力的血细胞形态学检验人才提供了显著教学支撑作用.

BackgroundEarly diagnosis of esophageal squamous cell carcinoma (ESCC) is critical for effective treatment and optimal prognosis; however, less study on serum biomarkers for the early ESCC detection has been reported. The aim of this study was to identify and evaluate several serum autoantibody biomarkers in early ESCC.MethodsWe initially screened candidate tumor-associated autoantibodies (TAAbs) associated with ESCC by serological proteome analysis (SERPA) combined with nanoliter-liquid chromatography combined with quadrupole time of flight tandem mass spectrometry (nano-LC-Q-TOF-MS/MS), and the TAAbs were further subjected to analysis by Enzyme-linked immunosorbent assay (ELISA) in a clinical cohort (386 participants, including 161 patients with ESCC, 49 patients with high-grade intraepithelial neoplasia [HGIN] and 176 healthy controls [HC]). Receiver operating characteristic (ROC) curve was plotted to evaluate the diagnostic performance.ResultsThe serum levels of CETN2 and POFUT1 autoantibodies which were identified by SERPA were statistically different between ESCC or HGIN patients and HC in ELISA analysis with the area under the curve (AUC) values of 0.709 (95%CI: 0.654-0.764) and 0.741 (95%CI: 0.689-0.793), 0.717 (95%CI: 0.634-0.800) and 0.703 (95%CI: 0.627-0.779) for detection of ESCC and HGIN, respectively. Combining these two markers, the AUCs were 0.781 (95%CI: 0.733-0.829), 0.754 (95%CI: 0.694-0.814) and 0.756 (95%CI: 0.686-0.827) when distinguishing ESCC, early ESCC and HGIN from HC, respectively. Meanwhile, the expression of CETN2 and POFUT1 was found to be correlated with ESCC progression.ConclusionsOur data suggest that CETN2 and POFUT1 autoantibodies have potential diagnostic value for ESCC and HGIN, which may provide novel insights for early ESCC and precancerous lesions detection.

Autoantibody (AAb) has a prominent role in prostate cancer (PCa), with few studies profiling the AAb landscape in Chinese patients. Therefore, the AAb landscape in Chinese patients was characterized using protein arrays. First, in the discovery phase, Huprot arrays outlined autoimmune profiles against ~ 21,888 proteins from 57 samples. In the verification phase, the PCa-focused arrays detected 25 AAbs selected from the discovery phase within 178 samples. Then, PCa was detected using a backpropagation artificial neural network (BPANN) model. In the validation phase, an enzyme-linked immunosorbent assay (ELISA) was used to validate four AAb biomarkers from 196 samples. Huprot arrays profiled distinct PCa, benign prostate diseases (BPD), and health AAb landscapes. PCa-focused array depicted that IFIT5 and CPOX AAbs could distinguish PCa from health with an area under curve (AUC) of 0.71 and 0.70, respectively. PAH and FCER2 AAbs had AUCs of 0.86 and 0.88 in discriminating PCa from BPD. Particularly, PAH AAb detected patients in the prostate-specific antigen (PSA) gray zone with an AUC of 0.86. Meanwhile, the BPANN model of 4-AAb (IFIT5, PAH, FCER2, CPOX) panel attained AUC of 0.83 among the two cohorts for detecting patients with gray-zone PSA. In the validation cohort, the IFIT5 AAb was upregulated in PCa compared to health ( p < 0.001). Compared with BPD, PAH and FCER2 AAbs were significantly elevated in PCa ( p = 0.012 and 0.039). We have demonstrated the first extensive profiling of autoantibodies in Chinese PCa patients, identifying novel diagnostic AAb biomarkers, especially for identification of gray-zone-PSA patients.

目的 探讨运动―心理―睡眠护理干预在乳腺癌患者放疗期间的应用效果,分析其对患者癌因性疲乏及心理状态的影响.方法 选取2019年1月至2021年1月间青岛市中心医院接受放射治疗的86例乳腺癌患者,采用随机数表法将其分为对照组和观察组,每组43例.对照组患者采用常规护理,观察组则在此基础上加用运动―心理―睡眠护理干预,记录患者焦虑(HAMA)、抑郁(HAMD)不良心理状态变化情况,评价两组患者干预前后的生活质量和癌因性疲乏状况.结果 干预前,两组患者疲乏量表各项得分及总分、HAMA、HAMD量表得分和生活质量量表各项得分比较,差异无统计学意义(P>0.05).干预后,两组疲乏量表各项得分均降低,观察组患者疲乏量表中行为、情感、感觉及总分均低于对照组,差异均有统计学意义(均P<0.05);观察组HAMA、HAMD量表得分均低于对照组,差异均有统计学意义(均P<0.05).观察组患者生活质量量表各项评分均高于对照组,差异均有统计学意义(均P<0.05).结论 与传统常规护理干预相比,运动―心理―睡眠护理干预可显著改善乳腺癌患者放疗期间的癌因性疲乏状况,缓解患者焦虑、抑郁的不良心理状态,进而提高其生活质量,应用效果良好,值得推荐.

Autoantibodies (AAbs) targeted tumor-associated antigens (TAAs) have the potential for early detection of breast cancer. Here, 574 early-stage breast cancer (ES-BC) patients containing 4 subtypes (Luminal A, Luminal B, HER2+, TN), 126 benign breast disease (BBD) patients, and 199 normal healthy controls (NHC) were separated into three-phases to discover, verify, and validate AAbs. In discovery phase using high-throughput protein microarray, 37 AAbs with sensitivity of 31.25%-86.25% and specificity over 73% in ES-BC, and 40 AAbs with different positive rates between subtypes were identified as candidates. In verification phase, 18 AAbs were significantly increased compared with the Control (BBD and NHC) in focused array. Ten out of 18 AAbs exhibited a significant difference between subtypes (P < .05). In ELISA validation phase, 5 novel AAbs (anti-KJ901215, -FAM49B, -HYI, -GARS, -CRLF3) exhibited significantly higher levels in ES-BC compared with BBD/NHC (P < .05). The sensitivities of individual AAb and a 5-AAbs panel were 20.41%-28.57% and 38.78%, whereas the specificities were over 90% and 85.94%. Simultaneously, 4 AAbs except anti-GARS differed significantly between TN and non-TN subtype (P < .05). We constructed 3 random forest classifier models based on AAbs to discriminant ES-BC from Control or BBD, and to discern TN subtype, which yielded an area under the curve of 0.870, 0.860, and 0.875, respectively. Biological interaction analysis revealed 4 TAAs, except for KJ901215, that were associated with well known proteins of BC. This study discovered and stepwise validated 5 novel AAbs with the potential to diagnose ES-BC and discern TN subtype, indicating easy-to-detect and minimally invasive diagnostic value of serum AAbs ahead of biopsy for future application.

Objective:To observe the efficacy and safety of camrelizumab combined with albumin-paclitaxel/lobaplatin as neoadjuvant therapy for locally advanced esophageal cancer.Methods:From 2019 to 2020, 18 patients with locally advanced esophageal squamous cell carcinoma who were initially unresectable were treated with neoadjuvant therapy of camrelizumab combined with albumin-paclitaxel/lobaplatin for 3-4 cycles before operation, and the operation was evaluated after treatment. The surgical removal rate (R 0), pathological complete response (pCR), major pathological response (MPR), the neoadjuvant objective response rate (ORR) and safety were observed. Results:The median age of 18 patients was 59 years (32-66 years). The neoadjuvant treatment completion rate was 89% (16/18). The R 0 rate was 61% (11/18), with pCR 45% (5/11), MPR 64% (7/11) and ORR 69%. The incidence of adverse reactions were neutropenia (78%), thrombocytopenia (61%) and reactive cutaneous capillary endothelial proliferation (61%), but the main adverse reactions were grade 1-2. The postoperative complications were mild. Conclusion:As a neoadjuvant therapy, camrelizumab combined with albumin-paclitaxel/lobaplatin can improve the pathological response rate of locally advanced esophageal cancer with good safety.

目的 建立新鲜血比对方案,完善血液分析仪日常室内质量控制(IQC),保证临床标本检测结果的可比性和一致性.方法 每日采用血液分析仪配套质控品完成IQC后,抽取检测结果在参考区间内,且血量约为2 mL的新鲜血标本.选择性能良好的血液分析仪作为靶机,以其他血液分析仪为比对仪器.以新鲜血标本在靶机中测定的结果作为靶值,比对仪器的测定结果作为测定值,比较靶值和测定值的差异,计算白细胞(WBC)计数、红细胞(RBC)计数、血红蛋白(Hb)、血细胞比容(HCT)、血小板(PLT)计数项目的相对偏差.仪器间相对偏差标准为1988年美国临床实验室改进法案(CLIA'88)允许误差的1/2,血液分析仪运行过程中的相对偏差标准为CLIA'88允许误差的1/3.根据偏差标准对相对偏差进行评价.结果 比对仪器与靶机的相对偏差符合1/2 CLIA'88允许误差的偏差范围的要求,仪器间检测结果具有可比性;血液分析仪运行过程比对数据的相对偏差符合1/3 CLIA'88允许误差的偏差范围的要求.结论 建立的新鲜血比对方案既能保证血液分析仪间检测结果的可比性和仪器运行过程中的稳定性,又能对血液分析仪进行方便、经济、有效的日常IQC.

Prostate cancer (PCa) is the second most frequently diagnosed cancer in men. However, its genetic characteristics in the Chinese population have not been extensively profiled. Here we screened 27 Chinese patients and preformed whole-genome sequencing to dissect their genomic patterns. We found that 18.5% (5/27) tumors harbored non-protein coding mutations on FOXA1. Besides, novel focal amplifications/deletions involving ZBTB7B, SLC4A4, TBX18, CYSLTR2 and EFNA5 were frequently present in tumors. Notably, group specificity of base substitution signature B displayed a strong link to hotspot mutations on SPOP gene. Furthermore, based on six rearrangement signatures, tumors were assigned to five subgroups that revealed different biological mechanisms. Of which, tandem duplicator subgroup harbored all CDK12 mutations, small deletor subgroup owned 75% TP53 changes, and large deletor subgroup had 66.7% SPOP mutations. Taken together, we provide a comprehensive view of genomic patterns which affect the critical cell regulators of PCa in the Chinese population. Our findings may provide valuable insights for designing specific treatments for Chinese patients with PCa.

目的 分析不合格血液标本的类型及分布情况,探讨相关整改措施,以确保分析前标本的质量.方法 回顾性分析我院检验科2018年接收的1 914份不合格血液标本的原因.并采取相应的改进措施.结果 5 694 572例送检血液标本中不合格标本总数1 914例,总不合格率0.034％.不合格原因前3位分别是:抗凝标本凝集、标本溶血、标本采集量错误.不合格血液标本所占比例最高的多为门诊抽血室,而特需病房(VIP病房)的比例最低.在不同专业组中,生化组的不合格血液标本率最高.结论 检验科应控制不合格血液标本并分析产生原因,采取有效对策,以便降低标本不合格率,确保分析前质量.

Background: Recently, a series of studies have been published to examine the possible diagnostic and prognostic values of glypican-3 (GPC3) in liver cancer with conflicting results observed. Thus, the present study aimed to assess the values of preoperative serum GPC3 alone and in combination with AFP for the diagnosis of liver cancer. Methods: An enzyme-linked immunoassay was used to quantify serum GPC3 in hepatocellular carcinoma group (HCC, n = 210), intrahepatic cholangiocarcinoma group (ICC, n = 36), combined hepatocellular cholangiocarcinoma group (cHCC-CC, n = 8), metastatic liver cancer group (MLC, n = 10) and normal controls (NC, n = 134). Results: The area under the curve (AUC) of GPC3 for HCC versus NC was 0.879, with a sensitivity of 79.52% at an optimal cutoff value of 0.0414 ng/mL; when GPC3 was combined with AFP, the AUC and sensitivity were increased to 0.925 and 88.10%, respectively. In addition, 43 of 68 AFP-negative patients had elevated GPC3 levels. Furthermore, the positive rate of GPC3 was significantly higher than the that of AFP for HCC in early stage. Conclusions: Serum GPC3 was superior to AFP for the diagnosis of early-stage HCC, and may be complementary to AFP for distinguishing HCC from NC.

目的 探讨血浆置换法对肿瘤患者乳糜血全血细胞分析的纠正作用.方法 选取2019年1月至2019年12月接收的经全血细胞分析后明确的乳糜血标本28例.先加入2 mL稀释液,依据乳糜血程度的不同,进行1～3次的血浆置换.重新进行全血细胞分析测定.比较置换前和置换后的白细胞(white blood cell,WBC)、红细胞(red blood cell,RBC)、血红蛋白(hemoglobin,HGB)、红细胞比容(hematocrit,HCT)、平均红细胞体积(mean corpuscular volume,MCV)、平均红细胞血红蛋白量(mean corpuscular hemoglobin,MCH)、平均红细胞血红蛋白浓度(mean corpuscular hemoglobin concentration,MCHC)、血小板(platelet,PLT)等指标的结果 .结果乳糜血标本因报警信息,全血细胞计数结果异常等情况而被发现.肿瘤患者乳糜血中结直肠癌所占比例最高.乳糜血标本经血浆置换后MCHC恢复到正常和(或)稳定的状态或与历史结果相符,表明已纠正乳糜血影响.血浆置换前后,全血细胞计数结果中的Hb、MCH、MCHC和PLT四项指标的差异具有统计学意义(P<0.05);而RBC、HCT、MCV和WBC的差异无统计学意义(P>0.05).结论 乳糜血干扰的主要参数指标为Hb、MCH、MCHC和PLT,血浆置换法可纠正这些被影响指标的结果,具有推广价值.

BACKGROUND Blood status is closely related to the hemoglobin test results in clinical laboratory. This paper discusses a case of which hemoglobin test results were not interfered by the "milky" blood status. METHODS Complete Blood Count with Differential (CBC + Diff) was detected for these two specimens with a Sysmex XN-9000. RESULTS The results of red cell indices for patient I were as follows: red blood cell count (RBC), 5.10 x 1012/L; hematocrit (HCT), 0.455 L/L; hemoglobin (HGB), 167 g/L; mean corpuscular hemoglobin concentration (MCHC), 367 g/L, and triglycerides (TG), 1.59 mmol/L. There was no "turbidity" warning message. However, there was a "turbidity" warning message for patient II and his red cell indices were RBC, 4.74 x 1012/L; HCT, 0.492 L/L; HGB, 182 g/L; MCHC, 370 g/L, and TG, 12.98 mmol/L. After the plasma exchange, there was no "turbidity" warning message for patient I and his red cell indices were RBC, 4.83 x 1012/L; HCT, 0.444 L/L; HGB, 164 g/L; MCHC, 369 g/L which were consistent with the results before the plasma exchange. For patient II, the "turbidity" warning message disappeared and his results were RBC, 3.87 x 1012/L; HCT, 0.398 L/L; HGB, 135 g/L; MCHC, 339 g/L. CONCLUSIONS Our case provided an explanation of the normal hemoglobin detection results in the visible lipemic specimen for the first time.

目的 探讨使用静脉血进行全血细胞分析的可接受样本量.方法 选择20例健康志愿者,用EDTA-K2定量的真空采血管分别采集1.0 mL、1.2 mL、1.4 mL、1.6 mL、1.8 mL和2.0 mL全血标本,在相同条件下分别将上述样本量的静脉血在Sysmex XN-9000全自动血细胞分析流水线上进行全血细胞计数检测.以2.0 mL作为标准量,将非标准量的全血细胞计数结果与其进行单因素方差分析,比较不同采血量全血细胞计数结果的差异.计算不同采血量全血细胞计数结果的相对偏差符合率.结果 非标准量与2.0 mL标准量的全血细胞计数结果差异无统计学意义(P>0.05).其相对偏差符合率均在临床可接受范围内,其中血小板(platelet,PLT)、平均红细胞体积(mean corpuscular volume,MCV)和平均红细胞血红蛋白量(mean corpuscular hemoglobin,MCH)的相对偏差符合率最高;红细胞(red blood cell,RBC)和红细胞比容(hematocrit,HCT)的相对偏差符合率较低.结论 静脉血全血细胞分析的可接受样本量为1.0～2.0 mL.